Leica Novocastra™ Immunohistochemistry Antibody (Hematologic Disorder and Blood Cancer Markers) - HSA Registration DE0509465
Access comprehensive regulatory information for Leica Novocastra™ Immunohistochemistry Antibody (Hematologic Disorder and Blood Cancer Markers) in the Singapore medical device market through Pure Global AI's free database. This CLASS B IVD medical device is registered under HSA registration number DE0509465 and owned by Leica Biosystems Newcastle Ltd. The device was registered on June 27, 2024.
This page provides complete registration details including product owner information, registrant details, importer information, and regulatory compliance data from the official Singapore HSA medical device database. Pure Global AI offers free access to Singapore's complete medical device registry, helping global MedTech companies navigate HSA regulations efficiently.
Intended for the qualitative identification by light microscopy of cancer marker molecules in paraffin sections. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient’s clinical history and other diagnostic tests by a qualified pathologist.